A study examining patients with post-infectious bronchiolitis obliterans (PIBO) suggests that azithromycin should be considered a therapeutic option for these patients.
According to the authors, since PIBO is a rare disorder, there are a limited number of reports and trials regarding treatment strategies, thus, therapeutic decisions are often empirically based. Treatment is often made through oral or inhaled corticosteroids.
The team emphasizes that PIBO patients should be treated by a multidisciplinary team and receive follow-up examination for an extended period. They suggest that oral azithromycin should be considered a therapeutic option for these patients given the fact that long-term therapy contributes to an improvement in patient’s condition. The team believes that patchy ground-glass opacity features on HRCT scans indicate BO, especially in children with persistent and severe wheezing, and that it is a feature that can be used to assess disease development.